in

The antibody drug conjugates market is projected to grow at an annualized rate of over 20%, till 203

Roots Analysis has done a detailed report on Antibody Drug Conjugates Market, covering various important aspects of the industry and identifying key future growth opportunities.

To order this 600+ page report, which features 190+ figures and 280+ tables, please visit this link

Key Market Insights 

  • Eminent representatives from different biopharmaceutical companies confirm the sustained interest in ADC therapeutics, highlighting the technological innovation that is driving contemporary R&D initiatives
  • Presently, over 240 ADC therapy candidates are being evaluated in clinical / preclinical stages for treating a variety of solid tumors / hematologic cancers
  • The pipeline features product candidates that target a wide range of biological antigens and are equipped with different cytotoxic warheads; a number of companies are focused on developing novel drug conjugates
  • In order to gain a competitive edge in the market, ADC developers are actively exploring new biological targets, conducting clinical trials across different geographies to treat diverse disease indications
  • A number of eminent scientists from renowned universities, owing to their involvement in clinical development efforts, have emerged as key opinion leaders within this market
  • Over the years, more than 16,000 patents related to ADCs have been filed / granted across the world, indicative of the ongoing pace of R&D activity in this field of research
  • Several investors, having realized the opportunity within this upcoming segment of targeted cancer therapeutics industry, have invested over USD 5 billion, in the period between 2011 and 2019
  • The increasing interest in this field is also reflected in the partnership activity; deals inked in the recent past were mostly focused on licensing of products / technologies, involving both international and indigenous stakeholders
  • In the recent years, several developer companies have initiated clinical trials to evaluate the therapeutic potential of ADCs in combination with other drug / therapy classes
  • Anticipating the launch of several product candidates, stakeholders are exploring diverse commercialization strategies across different stages of the launch cycle along with the appropriate reimbursement strategies
  • Given the complexities associated with the development and production of ADCs, CMOs are indispensable to the R&D and manufacturing activity in this domain; some CMOs have even pioneered the novel ADC technology platforms
  • Case Study: In order to keep patients and healthcare professionals informed and aware of the developments, companies are deploying diverse promotional strategies for their respective products
  • With a promising development pipeline and encouraging clinical results, the global market is anticipated to witness growth at an annualized rate of over 20% during the next decade
  • The anticipated future opportunity is likely to be distributed across different types of linkers and target antigens as more late-stage drugs get commercialized and existing marketing authorizations are expanded

For more information, please visit https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html

 

Table of Contents

 

1. PREFACE

1.1. Scope of the Report

1.2. Research Methodology

1.3. Chapter Outlines

 

2. EXECUTIVE SUMMARY

 

3. INTRODUCTION

3.1. Chapter Overview

3.2. Evolution of Anticancer Therapy

3.3. Cancer Treatment Methods

3.3.1. Surgery

3.3.2. Radiation Therapy

3.3.3. Chemotherapy

3.3.4. Targeted Therapies

 

3.4. Monoclonal Antibody-Based Anticancer Therapies

3.5. Components of Antibody Drug Conjugates (ADCs)

3.5.1. Antibody

3.5.2. Cytotoxin

3.5.3. Linker

 

3.6. Advantages of ADC Therapeutics over Traditional Therapeutic Interventions

3.7. Differences Between Small Molecule Drugs, Monoclonal Antibody Therapies and ADCs

3.8. Pharmacokinetic Properties of ADCs

3.8.1. Absorption

3.8.2. Distribution

3.8.3. Metabolism and Excretion

 

4. MARKET OVERVIEW

4.1. Chapter Overview

4.2. ADC Therapeutics: Clinical Pipeline

4.2.1. Analysis by Phase of Development

4.2.2. Analysis by Indication

4.2.3. Analysis by Line of Treatment

4.2.4. Analysis by Dosing Regimen

4.2.5. Analysis by Type of Therapy

4.2.6. Analysis by Target Antigen

4.2.7. Analysis by Antibody Origin

4.2.8. Analysis by Antibody Isotype

4.2.9. Analysis by Type of Linker

4.2.10. Analysis by Type of Payload / Warhead

4.2.11. Key Technology Providers

4.2.12. Discontinued Drugs

 

4.3. ADC Therapeutics: Preclinical Pipeline

4.3.1. Analysis by Phase of Development

4.3.2. Analysis by Indication

4.3.3. Analysis by Target Antigen

4.3.4. Key Players: Analysis by Number of ADC Therapeutics

 

4.4. ADC Therapeutics: Developer Landscape

4.4.1. Analysis by Year of Establishment

4.4.2. Analysis by Company Size

4.4.3. Analysis by Geographical Location

4.4.4. Logo Landscape: Analysis by Size and Target Indication

4.5. Novel Drug Conjugates

 

5. COMPANY AND DRUG PROFILES

5.1. Chapter Overview

5.2. AbbVie

5.2.1. Company Overview

5.2.2. Financial Information

5.2.3. Pipeline Overview

5.2.3.1. Rovalpituzumab Tesirine / ROVA-T

5.2.3.1.1 Drug Overview

5.2.3.1.2. Mechanism of Action

5.2.3.1.3. Clinical Development Status

5.2.3.1.4. Key Clinical Trial Results

 

5.2.3.2. Teliso-V / Telisotuzumab Vedotin / ABBV-399

5.2.3.2.1 Drug Overview

5.2.3.2.2. Mechanism of Action

5.2.3.2.3. Clinical Development Status

5.2.3.2.4. Key Clinical Trial Results

5.2.4. Recent Developments and Future Outlook

 

5.3. Astellas Pharma

5.3.1. Company Overview

5.3.2. Financial Information

5.3.3. Pipeline Overview

5.3.3.1. Enfortumab Vedotin

5.3.3.1.1. Drug Overview

5.3.3.1.2. Mechanism of Action

5.3.3.1.3. Clinical Development Status

5.3.3.1.4. Key Clinical Trial Results

 

5.3.3.2. ASG16-M8F

5.3.3.2.1. Drug Overview

5.3.3.2.2. Mechanism of Action

5.3.3.2.3. Clinical Development Status

5.3.3.2.4. Key Clinical Trial Results

5.3.4. Recent Developments and Future Outlook

5.4. AstraZeneca

54.1. Company Overview

5.4.2. Financial Information

5.4.3. Pipeline Overview

5.4.3.1. LUMOXITI™

5.4.3.1.1. Drug Overview

5.4.3.1.2. Mechanism of Action

5.4.3.1.3. Clinical Development Status

5.4.3.1.4. Key Clinical Trial Results

5.4.4. Recent Developments and Future Outlook

 

5.5. Daiichi Sankyo

5.5.1. Company Overview

5.5.2. Financial Information

5.5.3. Pipeline Overview

5.5.3.1. Trastuzumab deruxtecan / DS-8201a / DS 8201

5.5.3.1.1. Drug Overview

5.5.3.1.2. Mechanism of Action

5.5.3.1.3. Clinical Development Status

5.5.3.1.4. Key Clinical Trial Results

5.5.4. Recent Developments and Future Outlook

 

5.6. ImmunoGen

5.6.1. Company Overview

5.6.2. Financial Information

5.6.3. Pipeline Overview

5.6.3.1. IMGN853 / Mirvetuximab soravtansine

5.6.3.1.1. Drug Overview

5.6.3.1.2. Mechanism of Action

5.6.3.1.3. Clinical Development Status

5.6.3.1.4. Key Clinical Trial Results

5.6.4. Recent Developments and Future Outlook

5.7. Immunomedics

5.7.1. Company Overview

5.7.2. Financial Information

5.7.3. Pipeline Overview

5.7.3.1. IMMU-130

5.7.3.1.1. Drug Overview

5.7.3.1.2. Mechanism of Action

5.7.3.1.3. Clinical Development Status

5.7.3.1.4. Key Clinical Trial Results

5.7.4. Recent Developments and Future Outlook

 

5.8. Pfizer

5.8.1. Company Overview

5.8.2. Financial Information

5.8.3. Pipeline Overview

5.8.3.1. CMC-544 / BESPONSA® / Inotuzumab Ozogamicin

5.8.3.1.1. Drug Overview

5.8.3.1.2. Mechanism of Action

5.8.3.1.3. Clinical Development Status

5.8.3.1.4. Key Clinical Trial Results

 

5.8.3.2. MYLOTARG™ / Gemtuzumab Ozogamicin

5.8.3.2.1. Drug Overview

5.8.3.2.2. Mechanism of Action

5.8.3.2.3. Clinical Development Status

5.8.3.2.4. Key Clinical Trial Results

5.8.4. Recent Developments and Future Outlook

 

5.9. Roche / Genentech

5.9.1. Company Overview

5.9.2. Financial Information

5.9.3. Pipeline Overview

5.9.3.1. KADCYLA®

5.9.3.1.1. Drug Overview

5.9.3.1.2. Mechanism of Action

5.9.3.1.3. Clinical Development Status

5.9.3.1.4. Key Clinical Trial Results

 

5.9.3.2. RG-7596

5.9.3.2.1. Drug Overview

5.9.3.2.2. Mechanism of Action

5.9.3.2.3. Clinical Development Status

5.9.3.2.4. Key Clinical Trial Results

5.9.4. Recent Developments and Future Outlook

 

5.10. Seattle Genetics

5.10.1. Company Overview

5.10.2. Financial Information

5.10.3. Pipeline Overview

5.10.3.1. ADCETRIS®

5.10.3.1.1. Drug Overview

5.10.3.1.2. Mechanism of Action

5.10.3.1.3. Clinical Development Status

5.10.3.1.4. Key Clinical Trial Results

 

5.10.3.2. SGN- LIV1A

5.10.3.2.1. Drug Overview

5.10.3.2.2. Mechanism of Action

5.10.3.2.3. Clinical Development Status

5.10.3.2.4. Key Clinical Trial Results

5.10.4. Recent Developments and Future Outlook

 

5.11. Synthon

5.11.1. Company Overview

5.11.2. Financial Information

5.11.3. Pipeline Overview

5.11.3.1. SYD985 / Trastuzumab Duocarmazine

5.11.3.1.1. Drug Overview

5.11.3.1.2. Mechanism of Action

5.11.3.1.3. Clinical Development Status

5.11.3.1.4. Key Clinical Trial Results

5.11.4. Recent Developments and Future Outlook

 

5.12. Other Companies

5.12.1. Bayer HealthCare

5.12.1.1. Company Overview

5.12.1.2. Financial Information

5.12.1.3. Pipeline Overview

5.12.1.4. Recent Developments and Future Outlook

 

5.12.2. Biotest Pharmaceuticals

5.12.2.1. Company Overview

5.12.2.2. Financial Information

5.12.2.3. Pipeline Overview

5.12.2.4. Recent Developments and Future Outlook

 

6. KEY THERAPEUTIC AREAS

6.1. Chapter Overview

6.2. Hematological Malignancies

6.2.1. Leukemias and Lymphomas

6.2.1.1. Leukemia: Introduction and Epidemiology

6.2.1.1.1. Acute Myeloid Leukemia

6.2.1.1.2. Chronic Myeloid Leukemia

6.2.1.1.3. Acute Lymphocytic Leukemia

6.2.1.1.4. Chronic Lymphocytic Leukemia

6.2.1.2. Lymphoma: Introduction and Epidemiology

6.2.1.3. Current Treatment Landscape

6.2.1.4. ADC Therapeutics for Leukemia / Lymphoma

 

6.2.2. Multiple Myeloma

6.2.2.1. Introduction and Epidemiology

6.2.2.2. Current Treatment Landscape

6.2.2.3. ADC Therapeutics for Multiple Myeloma

 

6.3. Solid Tumors

6.3.1. Lung Cancer

6.3.1.1. Introduction and Epidemiology

6.3.1.2. Current Treatment Landscape

6.3.1.3. ADC Therapeutics for Lung Cancer

 

6.3.2. Breast Cancer

6.3.2.1. Introduction and Epidemiology

6.3.2.2. Current Treatment Landscape

6.3.2.3. ADC Therapeutics for Breast Cancer

 

6.3.3. Ovarian Cancer

6.3.3.1. Introduction and Epidemiology

6.3.3.2. Current Treatment Landscape

6.3.3.3. ADC Therapeutics for Ovarian Cancer

 

6.3.4. Bladder Cancer

6.3.4.1. Introduction and Epidemiology

6.3.4.2. Current Treatment Landscape

6.3.4.3. ADC Therapeutics for Bladder Cancer

 

6.3.5. Colorectal Cancer

6.3.5.1. Introduction and Epidemiology

6.3.5.2. Current Treatment Landscape

6.3.5.3. ADC Therapeutics for Colorectal Cancer

 

6.3.6. Prostate Cancer

6.3.6.1. Introduction and Epidemiology

6.3.6.2. Current Treatment Landscape

6.3.6.3. ADC Therapeutics for Prostate Cancer

 

6.3.7. Gastric Cancer

6.3.7.1. Introduction and Epidemiology

6.3.7.2. Current Treatment Landscape

6.3.7.3. ADC Therapeutics for Prostate Cancer

 

7. KEY OPINION LEADERS

7.1. Chapter Overview

7.2. Methodology

 

7.3. Principal Investigators / Sub-Investigators / Study Directors Involved in Clinical Trials

7.3.1. Geographical Distribution of Key Opinion Leaders

7.3.1.1. Experts on ADCETRIS®

7.3.1.2. Experts on KADCYLA®

7.3.1.3. Experts on MYLOTARG™

7.3.1.4. Experts on Other ADCs

 

7.4. Prominent Key Opinion Leaders (KOLs)

7.5. KOL Benchmarking: Roots Analysis versus Third Party Scoring (ResearchGate Score)

 

7.6. Most Active Key Opinion Leaders

7.6.1. Profile: KOL A (Celgene)

7.6.2. Profile: KOL B (Western Regional Medical Center)

7.6.3. Profile: KOL C (MedStar Washington Hospital Center)

7.6.4. Profile: KOL D (Cancer Institute and Hospital)

7.6.5. Profile: KOL E (Comprehensive Cancer Centers of Nevada)

7.6.6. Profile: KOL F (Hopital Tenon)

7.6.7. Profile: KOL G (Cleveland Clinic)

 

8. TARGET COMPETITIVENESS ANALYSIS

8.1. Chapter Overview

8.2. Scope and Methodology

8.3. Competitiveness Analysis: Key Clinical Targets for ADCs

8.3.1. Four-Dimensional Bubble Analysis

8.3.2 Five-Dimensional Spider Web Analysis

 

8.4. Competitiveness Analysis: Key Preclinical Targets for ADCs

8.4.1. Two-Dimensional Scatter Plot Analysis

 

9. PARTNERSHIPS AND COLLABORATIONS

9.1. Chapter Overview

9.2. Partnership Models

9.3. ADC Therapeutics: List of Partnerships and Collaborations

9.3.1 Analysis by Year of Partnerships

9.3.2. Analysis by Type of Partnerships

9.3.3. Most Active Players: Analysis by Number of Partnerships

 

9.3.4. Regional Analysis

9.3.4.1. Intercontinental and Intracontinental Agreements

 

10. FUNDING AND INVESTMENT ANALYSIS

10.1. Chapter Overview

10.2. Types of Funding

10.3. ADC Therapeutics: Funding and Investment Analysis

10.3.1. Analysis by Number of Instances

10.3.2. Analysis by Amount Invested

10.3.3. High Value Deals: Analysis by Year

10.3.4. Analysis by Type of Funding

 

10.3.5. Most Active Players

10.3.5.1. Analysis by Number of Funding Instances

10.3.5.2. Analysis by Amount Invested

10.4. Concluding Remarks

 

11. PATENT ANALYSIS

11 Patent Analysis

11.1. Chapter Overview

11.2. Scope and Methodology

11.3. ADC Therapeutics: Patent Analysis

11.3.1. Analysis by Publication Year

11.3.2. Analysis by Geographical Location

11.3.3. Analysis by CPC Classification

11.3.4. Emerging Focus Areas

11.3.5. Analysis by Type of Industry

11.3.6. Leading Players: Analysis by Number of Patents

11.4. ADC Therapeutics: Patent Benchmarking Analysis (Industry Players)

11.4.1. Analysis by Patent Characteristics

11.4.2. Analysis By Geographical Location

11.5. ADC Therapeutics: Patent Valuation Analysis

 

12. ACADEMIC GRANTS

12.1. Chapter Overview

12.2. Scope and Methodology

12.3. ADC Therapeutics: List of Academic Grants

12.3.1. Analysis by Number of Grants

12.3.2. Analysis by Type of Grant

12.3.3. Analysis by Grant Amount

12.3.4. Analysis by Focus Area

12.3.5. Analysis by Support Period

 

12.4. Leading Organizations: Analysis by Number of Grants

12.5. Analysis by Type of Recipient Organization

12.6. Analysis by Administering Institute Center

12.7. Analysis by Funding Institute Center

12.8. Key Project Leaders: Analysis by Number of Grants

 

13. KEY COMMMERCIALIZATION STRATEGIES

13.1. Chapter Overview

13.2. Successful Drug Launch Strategy: ROOTS Framework

13.3. Successful Drug Launch Strategy: Product Differentiation

13.4. Common Commercialization Strategies Adopted Based on Development Stage of Product

 

13.5. Approved Molecules for ADCs

13.5.1. ADCETRIS®

13.5.2. KADCYLA®

13.5.3. MYLOTARG™

13.5.4. BESPONSA®

13.5.5. LUMOXITI™

13.5.5. POLIVY™

 

13.6. Key Commercialization Strategies Adopted by Companies Developing ADCs

13.6.1. Strategies Adopted Before Drug Approval

13.6.1.2. Collaboration with Internal Stakeholders and Pharmaceutical Firms

 

13.6.2. Strategies Adopted During / Post Drug Approval

13.6.2.1. Geographical Expansion

13.6.2.2. Participation in Global Events

13.6.2.3. Awareness Through Product Websites

13.6.2.4. Collaboration with Internal Stakeholders and Pharmaceutical Firms

13.7. Concluding Remarks

 

14. PROMOTIONAL ANALYSIS

14.1. Chapter Overview

14.2. Channels Used for Promotional Campaigns

14.3. Summary of Product Website Analysis

14.4. Summary of Patient Brochure and Informative Downloads

 

14.5. ADCETRIS®: Promotional Analysis

14.5.1. Product Website Analysis

14.5.1.1. Messages for Healthcare Professionals

14.5.1.2. Messages For Patients

14.5.2. Patient Support Services and Informative Downloads

14.5.3. Other Promotional Activities

14.5.3.1. Presence in Conferences

 

14.6. KADCYLA®: Promotional Analysis

14.6.1. Product Website Analysis

14.6.1.1. Messages for Healthcare Professionals

14.6.1.2. Messages for Patients

14.6.2. Patient Support Services and Informative Downloads

14.6.3. Other Promotional Activities

14.6.3.1. Presence in Conferences

 

14.7. MYLOTARG™: Promotional Analysis

14.7.1. Product Website Analysis

14.7.1.1. Messages for Healthcare Professionals

14.7.1.2. Messages for Patients

14.7.2. Patient Support Services and Informative Downloads

14.7.3. Other Promotional Activities

14.7.3.1. Presence in Conferences

 

14.8. BESPONSA®: Promotional Analysis

14.8.1. Product Website Analysis

14.8.1.1. Messages for Healthcare Professionals

14.8.1.2. Messages for Patients

14.8.2. Patient Support Services and Informative Downloads

14.8.3. Other Promotional Activities

14.8.3.1. Presence in Conferences

 

14.9. LUMOXITI™: Promotional Analysis

14.9.1. Product Website Analysis

14.9.1.1. Messages for Healthcare Professionals

14.9.1.2. Messages for Patients

14.9.2. Patient Support Services and Informative Downloads

14.9.3. Other Promotional Activities

14.9.3.1. Presence in Conferences

 

14.10. POLIVY™: Promotional Analysis

14.10.1. Product Website Analysis

14.10.1.1. Messages for Healthcare Professionals

14.10.1.2. Messages for Patients

14.10.2. Patient Support Services and Informative Downloads

14.10.3. Other Promotional Activities

14.10.3.1. Presence in Conferences

 

15. COMBINATION THERAPIES

15.1. Chapter Overview

15.2. Combination Therapy: History of Development

15.3. FDA-approved Combination Therapies in Oncology

 

15.4. Combination Therapy: FDA Guidelines

15.4.1. Combinations of Marketed Drugs

15.4.2. Combinations of Marketed Drugs with New Molecular Entities

15.4.3. Combinations of New Molecular Entities

 

15.5. Combination Therapies: ADCs

15.5.1. Completed / Ongoing Clinical Studies of ADCs

15.5.1.1. Analysis by Type of Therapy

15.5.2. Completed / Ongoing Clinical Studies of ADC-based Combination Therapies

15.5.2.1. Analysis by Highest Phase of Development

15.5.2.2. Analysis by Current Trial Status

15.5.2.3. Analysis by Type of Combination

15.5.2.4. Analysis by Indication and Type of Combination

 

16. NOVEL CONJUGATION TECHNOLOGY PLATFORMS

16.1. Chapter Overview

16.2. First Generation ADC Technologies

 

16.3. Second Generation ADC Technologies

16.3.1. Cysteine and Selenocysteine Engineering

16.3.2. Unnatural Amino Acid Engineering

16.3.3. Amino-Terminal Engineered Serine

 

16.4. Third Generation ADC Technologies

16.4.1. Enzyme-Assisted Ligation Approaches

16.4.2. Glycan Remodeling Approaches

16.4.3. Ligation at Fab Nucleotide-Binding Site

16.4.4. Cysteine Rebridging

16.4.5. Preventing / Limiting Retro-Michael Drug Deconjugation

16.5. Evolutionary Analysis of Conjugation Technologies

 

17. ASSESMENT OF NON-CLINICAL DATA, FIRST IN HUMAN DOSING

17.1. Chapter Overview

17.2. ADCs and Non-Clinical Studies

17.3. ICH S9 Guidelines

 

17.4. Investigational New Drug (IND)-Enabling Study Designs

17.4.1. Example Case: KADCYLA®

 

17.5. Toxicities in Animal Models

17.6. Prediction of Maximum Tolerated Dosage (MTD) in Humans

17.7. Other Key Considerations for Study Design

 

18. COST PRICE ANALYSIS

18.1. Chapter Overview

18.2. Factors Contributing Towards the High Price of ADC Therapeutics

18.3. ADC Therapeutics Market: Pricing Models

18.3.1. On the Basis of Associated Costs

18.3.2. On the Basis of Competition

18.3.3. On the Basis of Patient Segment

18.4. Reimbursement Considerations for ADC Therapeutics

 

19. CASE STUDY: CONTRACT MANUFACTURING OF ADC

19.1. Chapter Overview

19.2. Key Steps for ADC Manufacturing

19.3. Technical Concerns Related to ADC Manufacturing

19.4. Challenges Associated with Supply Chain and Method Transfer

19.5. Limitations of In-House Manufacturing

19.6. Investments in ADC Manufacturing Capability Expansions

19.7. Collaborations Established for ADC Manufacturing

19.8. Growing Demand for Contract Manufacturing

19.9. Emergence of Start-Ups Offering Contract Services

19.10. CMOs with Linker Manufacturing Capabilities

19.11. CMOs with HPAPI / Cytotoxic Payload Manufacturing Capabilities

19.12. CMOs with Conjugation Capabilities

19.13. ADC One Stop Shops

 

20. CASE STUDY: COMPANION DIAGNOSTICS FOR ADC THERAPEUTICS

20.1. Chapter Overview

20.1.1. Advantages of Companion Diagnostics

20.1.2. Disadvantages of Companion Diagnostics

 

20.2. Companion Diagnostics for ADC Therapeutics

20.3. ADC Therapeutics: List of Companion Diagnostics

20.3.1. Analysis by Type of Target

20.3.2. Analysis by Type of Cancer Indication

20.4. Concluding Remarks

 

21. MARKET FORECAST AND OPPORTUNITY ANALYSIS

21.1. Chapter Overview

21.2. Scope and Limitations

21.3. Forecast Methodology

 

21.4. Overall ADC Therapeutics Market

21.4.1. ADC Therapeutics Market: Distribution by Target Indication

21.4.2. ADC Therapeutics Market: Distribution by Type of Linker

21.4.3. ADC Therapeutics Market: Distribution by Type of Payload

21.4.4. ADC Therapeutics Market: Distribution by Target Antigen

21.4.5. ADC Therapeutics Market: Distribution by Geography

21.4.6. ADC Therapeutics Market: Distribution by Technology Providers

 

21.5. ADC Therapeutics Market: Individual Drug Sales Forecasts

21.5.1. ADCETRIS® / Brentuximab Vedotin

21.5.1.1. Target Patient Population

21.5.1.2. Sales Forecast

 

21.5.2. KADCYLA® / Ado-trastuzumab Emtansine

21.5.2.1. Target Patient Population

21.5.2.2. Sales Forecast

 

21.5.3. MYLOTARG™ / Gemtuzumab Ozogamicin

21.5.3.1. Target Patient Population

21.5.3.2. Sales Forecast

 

21.5.4. BESPONSA® / Inotuzumab Ozogamicin

21.5.4.1. Target Patient Population

21.5.4.2. Sales Forecast

 

21.5.5. LUMOXITI™

21.5.5.1. Target Patient Population

21.5.5.2. Sales Forecast

 

21.5.6. POLIVYTM / Polatuzumab vedotin-piiq / RG7596

21.5.6.1. Target Patient Population

21.5.6.2. Sales Forecast

 

21.5.7. ASG-22ME / Enfortumab Vedotin

21.5.7.1. Target Patient Population

21.5.7.2. Sales Forecast

 

21.5.8. BAT8001

21.5.8.1. Target Patient Population

21.5.8.2. Sales Forecast

 

21.5.9. DS-8201a / DS 8201 / Trastuzumab Deruxtecan

21.5.9.1. Target Patient Population

21.5.9.2. Sales Forecast

 

21.5.10. IMMU-132 / Sacituzumab Govitecan

21.5.10.1. Target Patient Population

21.5.10.2. Sales Forecast

 

21.5.11. IMGN853 / Mirvetuximab Soravtansine

21.5.11.1. Target Patient Population

21.5.11.2. Sales Forecast

 

21.5.12. lpituzumab TesirineRova-T / Rova

21.5.12.1. Target Patient Population

21.5.12.2. Sales Forecast

 

21.5.13. SYD985 / Trastuzumab Duocarmazine

21.5.13.1. Target Patient Population

21.5.13.2. Sales Forecast

 

21.5.14. ABBV-399 / Teliso-V / Telisotuzumab Vedotin

21.5.14.1. Target Patient Population

21.5.14.2. Sales Forecast

 

21.5.15. ADCT-301 / HuMax-TAC-ADC / Camidanlumab Tesirine

21.5.15.1. Target Patient Population

21.5.15.2. Sales Forecast

 

21.5.16. ADCT-402 / Loncastuximab Tesirine

21.5.16.1. Target Patient Population

21.5.16.2. Sales Forecast

 

21.5.17. AGS 16M8F / AGS 16C3F

21.5.17.1. Target Patient Population

21.5.17.2. Sales Forecast

 

21.5.18. AVID100

21.5.18.1. Target Patient Population

21.5.18.2. Sales Forecast

 

21.5.19. BAY 94-9343

21.5.19.1. Target Patient Population

21.5.19.2. Sales Forecast

 

21.5.20. GSK 2857916 / Anti-BCMA ADC

21.5.20.1. Target Patient Population

21.5.20.2. Sales Forecast

 

21.5.21. HuMax-TF-ADC / Tisotumab Vedotin

21.5.21.1. Target Patient Population

21.5.21.2. Sales Forecast

 

21.5.22. IMGN529 / Debio 1562 / Naratuximab Emtansine

21.5.22.1. Target Patient Population

21.5.22.2. Sales Forecast

 

21.5.23. IMMU-130 / Sacituzumab Govitecan

21.5.23.1. Target Patient Population

21.5.23.2. Sales Forecast

 

21.5.24. RC48

21.5.24.1. Target Patient Population

21.5.24.2. Sales Forecast

 

21.5.25. SGN-LIV1A / Ladiratuzumab Vedotin

21.5.25.1. Target Patient Population

21.5.25.2. Sales Forecast

 

22. SWOT ANALYSIS

22.1. Chapter Overview

22.2. Strengths

22.3. Weaknesses

22.4. Opportunities

22.5. Threats

22.6. Comparison of SWOT Factors

22.7. Concluding Remarks

 

23. CONCLUSION

23.1. Chapter Overview

23.2. Key Takeaways

 

24. EXECUTIVE INSIGHTS

24.1. Chapter Overview

24.2. Abzena

24.2.1. Company Snapshot

24.2.2. Interview Transcript: John Burt, Chief Executive Officer

 

24.3. Ajinomoto Bio-Pharma Services

24.3.1. Company Snapshot

24.3.2. Interview Transcript: Tatsuya Okuzumi, Associate General Manager

 

24.4. BSP Pharmaceuticals

24.4.1. Company Snapshot

24.4.2. Interview Transcript: Aldo Braca, President and Chief Executive Officer and Giorgio Salciarini, Technical Business Development Senior Manager

 

24.5. Catalent Pharma Solutions

24.5.1. Company Snapshot

24.5.2. Interview Transcript: Jennifer L. Mitcham, Director, SMARTag ADCs and Bioconjugates, and Stacy McDonald, Group Product Manager

 

24.6. Cardiff University

24.6.1. Company Snapshot

24.6.2. Interview Transcript: Alan Burnett, Professor, School of Medicine

 

24.7. Cerbios-Pharma

24.7.1. Company Snapshot

24.7.2. Interview Transcript: Denis Angioletti, Chief Commercial Officer

 

24.8. Eisai

24.8.1. Company Snapshot

24.8.2. Interview Transcript: Toshimitsu Uenaka, Executive Director and Takashi Owa, Chief Innovation Officer

 

24.9. Lonza

24.9.1. Company Snapshot

24.9.2. Interview Transcript: Laurent Ducry, Head of Bioconjugates Commercial Development

 

24.10. NBE-Therapeutics

24.10.1. Company Snapshot

24.10.2. Interview Transcript: Wouter Verhoeven, Chief Business Officer

 

24.11. Oxford BioTherapeutics

24.11.1. Company Snapshot

24.11.2. Interview Transcript: Christian Rohlff, Chief Executive Officer and Founder

 

24.12. Pierre Fabre

24.12.1. Company Snapshot

24.12.2. Interview Transcript: Christian Bailly, Director of CDMO

 

24.13. Piramal Healthcare

24.13.1. Company Snapshot

24.13.2. Interview Transcript: Mark Wright, Site Head, Grangemouth

 

24.14. Synaffix

24.14.1. Company Snapshot

24.14.2. Interview Transcript: Anthony DeBoer, Director, Business Development

 

24.15. Syndivia

24.15.1. Company Snapshot

24.15.2. Interview Transcript: Sasha Koniev, Chief Executive Officer and Co-Founder

 

24.16. Anonymous, Director, Business Development, Leading CMO

24.17. Anonymous, Chief Executive Officer, Leading CMO

 

25. APPENDIX 1: TABULATED DATA

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

This post was created with our nice and easy submission form. Create your post!

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

GIPHY App Key not set. Please check settings

Loading…

0

What do you think?

Following the Correction, This is Why Now is the Time to Buy Bitcoin for the Long-Term: Analysis

Following the Correction, This is Why Now is the Time to Buy Bitcoin for the Long-Term: Analysis

Ripple Reveals Push To Expand Institutional XRP Liquidity in Asia, Launches Hiring Spree for RippleX

Ripple Reveals Push To Expand Institutional XRP Liquidity in Asia, Launches Hiring Spree for RippleX